Treatment with TMS at UCLA is administered by the TMS Treatment Service. Our physicians are Board-Certified Psychiatrists and full-time professors of Psychiatry at UCLA, each with years of experience in the treatment of depression and other complex mood disorders and with specific training in neuromodulation techniques. We are ably assisted by other members of our treatment team, who come from diverse backgrounds including nursing and psychology. Our team at UCLA was the first service within the University of California system to offer TMS treatment to patients.
Individuals who are seeking care with TMS at UCLA are initially evaluated by one of the physicians on our team, Drs. Leuchter, Krantz, Levitt, Cook, or Minzenberg. The objective of this consultation is to get to know a prospective individual patient's clinical situation, how their mood disorder has impacted their life, what treatments may have been tried before (and what the outcomes were), and any medical issues that may bear on the safe administration of TMS. We seek to ensure the highest quality of care for individuals with depression, whether that means treatment with TMS or whether we may recommend some other alternative.
All treatment planning and stimulation sessions are conducted by our Psychiatrists.
Treatments are administered in our state-of-the-art Neuromodulation Suite in the Semel Institute (Neuropsychiatric Institute) Building, 760 Westwood Blvd, Los Angeles, on the UCLA Campus (map, directions). For TMS treatments in depression, we employ an FDA-approved system for therapeutic TMS, the NeuroStar TMS Therapy System (Neuronetics, Inc., Malvern PA).
Andrew F. Leuchter, MD, is a Professor in the Department of Psychiatry and Biobehavioral Science, Director of the Neuromodulation Division, and a Senior Research Scientist at the Semel Institute for Neuroscience and Human Behavior at UCLA. A graduate of Stanford University, Dr. Leuchter earned his medical degree from Baylor College of Medicine in Houston, Texas. He joined the UCLA faculty in 1986.
An internationally recognized expert on the treatment of mood disorders, Dr. Leuchter’s research focuses on the enhancement of treatment outcomes in depression. He directs the Transcranial Magnetic Stimulation (TMS) Service in the Division, which performs more than 2,500 treatments each year for patients with depression, pain, and other neuropsychiatric illness. He is leading clinical trials to develop novel neuromodulation technologies for treatment of depression and Post-Traumatic Stress Disorder (PTSD), including synchronized Transcranial Magnetic Stimulation (sTMS) and Trigeminal Nerve Stimulation (TNS). He uses brain-imaging techniques, such as quantitative electroencephalography (qEEG), magnetic resonance imaging (MRI), and positron emission tomography (PET), to examine brain function and predict which treatments are most likely to benefit individual patients. Dr. Leuchter’s research program combines clinical trials with neurophysiologic and brain-imaging studies to inform clinical practice in the treatment of depression. As a Board certified electroencephalographer, he has unique expertise in development of biomarkers and has shown that brain oscillation patterns can be used to determine highly beneficial and individualized treatment.
Dr. Leuchter is a Diplomat of the American Board of Electroencephalography and Neurophysiology and a Diplomat in Psychiatry and Neurology with Added Qualifications in Geriatric Psychiatry. He is a member of several professional organizations, including the American Psychiatric Association, American Psychiatric Electrophysiology Association, and the American Medical EEG Association. He has authored over 150 scientific articles on topics including neuromodulation for the treatment of depression, biomarkers to guide treatment of neuropsychiatric illness, and theories of antidepressant action. He also maintains an active clinical practice, specializing in consultation for and care of patients suffering from treatment-resistant depression.
For more information on Dr. Leuchter, please visit: www.andrewleuchter.com
David Krantz is a Professor in Residence in the Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine at UCLA.
An undergraduate at Brown University, he completed an MD/PhD in the Medical Scientist Training Program at UCLA in 1991, where he performed his dissertation on Drosophila eye development with Larry Zipursky. After a residency in psychiatry at UCLA, he was awarded a Howard Hughes Postdoctoral Fellowship for Physicians to investigate the regulation of vesicular neurotransmitter transporters in Robert Edwards' laboratory at UCSF.
He returned to UCLA in 2000, and is currently using Drosophila to study how changes in the function of neurotransmitter transporters may influence synaptic transmission and behavior.
Medical Board Certifications:
Psychiatry, American Board of Psychiatry and Neurology, 1993
Child & Adolescent Psychiatry, American Board of Psychiatry and Neurology, 1994
Psychiatry, Stanford University School of Medicine, 1990-1991
Psychiatry, Stanford University School of Medicine, 1987-1990
Child Psychiatry, UCLA Neuropsychiatric Hospital, 1991-1993
Internal Medicine, University of North Carolina Hospitals, 1986-1987
University of North Carolina, Chapel Hill, School of Medicine, MD, 1986
Medical Board Certifications:
Psychiatry, American Board of Psychiatry and Neurology, 2002, 2012
Psychiatry, UCSF Department of Psychiatry, 1996-1999
Psychiatry, UCSF Department of Psychiatry, 1995-1996
McGill University Faculty of Medicine, MD, 1995
|Joel Diaz||TMS & EEG Technician|
|Michelle Abrams, RN||Nurse|
|Nikita Vince-Cruz||Research Manager|
|Jola Leskinen||TMS Technician|
|Alex Afewerki||TMS Technician|
|Thien Nghiem||TMS Technician|
|Kristine Reina||TMS Intake Coordinator|
|Lydia Nguyen||TMS Intake Coordinator|